TRUVESIC
Live / Applied — First extension granted (statement of use) (as of 18 Feb 2026)
What this means for you
Not registered yet, but its 04 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98884796
- Mark type
- Word mark
- Filed
- 04 Dec 2024
- Published for opposition
- 24 Jun 2025
- Attorney of record
- Perry J. Viscounty
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer, pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing
Owner
- CG Oncology, Inc., Irvine, CA, US
- CG Oncology, Inc., Irvine, CA, US
Prosecution history
- 19 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Feb 2026 — SOU EXTENSION 1 GRANTED
- 18 Feb 2026 — SOU EXTENSION 1 FILED
- 18 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 19 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Jun 2025 — PUBLISHED FOR OPPOSITION
- 18 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 May 2025 — ASSIGNED TO EXAMINER
- 17 May 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 04 Dec 2024 — NEW APPLICATION ENTERED